GMC (Thumbay) Hospital launches Cath Lab services in Ajman

[email protected] (Media Release)
January 26, 2015

Ajman, Jan 26: The Gulf Medical College (Thumbay) Hospital Ajman, the 1st JCI Accredited Hospital in Ajman expanded its advanced range of services by launching a state-of-the-art Cath Lab.

Sheikh Humaid Bin Rashid Al Nuaimi, Member of the Supreme Council UAE and Ruler of Ajman inaugurated the CATH LAB in the presence of Mr. Thumbay Moideen, Founder President of Thumbay Group.

He was accompanied by Sheikh Abdul Aziz bin Humaid Al Nuaimi, Sheikh Ahmed Bin Humaid Al Nuaimi, Sheikh Rashid Bin Humaid Al Nuaimi and His Excellency Sheikh Dr. Majid Bin Saeed Al Nuaimi. Mr. Akbar Moideen Thumbay Director Healthcare and Retail, Thumbay Group UAE,other dignitaries, officials from the ministries, medical equipment companies and the hospital management were present on the occasion.International experts like Dr Anil K D’Cruz, Director Tata Memorial Hospital, Mumbai, India, Mr. Dennis Brown, Corporate Chief Executive Officer, Bumrungrad International Hospital, Bangkok, Thailand, Dr Christian Taube, CEO, UKE Consult & Management GmbH, Hamburg, Germany, Dr. Vivek Desai, Managing Director, Hosmac India Pvt Ltd, Mumbai, India, and Dr Mounes Kalaawi, CEO, Clemenceau Medical Center, Beirut, Lebanon were also present.

With the addition of this state-of-the-art facility, the Cath lab will expand the hospital's capacity to treat steeply increasing heart and artery-related health issues of the region.“Our aim is to continue delivering the best healthcare in the region through the use of latest technology," said Akbar Moideen.

The Cardiology Department of GMC (THUMBAY) Hospital Ajman specializes in all kind of cardiology services including Interventional cardiology;GMC Hospital has the First Hybrid Cath lab in Ajman. We have with us renowned cardiac specialists who perform emergency Interventional Cardiac Treatment said Dr. Manvir Singh Walia, Administrative Director, Healthcare Division, Thumbay Group UAE.The benefit of having both surgical equipment and high-end angiographic equipment is the ability to perform coordinated and specialized, tailored approaches to unique cardiologic problems explained Dr. Walia.

GMC (THUMBAY) Hospital Ajman has highly qualified cardiologists with extensive experience in endovascular interventions. Besides performing the regular interventional procedures, which includes balloon and stents for Coronary Artery Disease .With a dedicated unit of four full-time Cardiologists and a team of junior doctors, nurses, and technicians trained to the highest standard in cardiac care, the specialists diagnose and manage full range of heart conditions. The lab is fully equipped with state-of-the-art facilities and complete range of services – from cardiac investigations to interventional cardiology procedures in ultramodern Catheterization Lab (Cath Lab).

The hospital, which caters to patients from over 175 countries, offers a multidisciplinary in-patient program, and also has complete coronary care unit for critical cardiac patients. For acute cardiac cases specially heart attacks to ensure that the patients go through timelytreatment according to recent clinical guidelines. Emergency patients are sent directly to Coronary Care Unit (CCU) or Cath Lab (if needed).

Thehospital offers 24/7emergency cardiac service for patients with acute heart attacks with international standards for emergency cathlab and coronary interventions.

Common procedures performed includeDirectional coronary artery stenting, Radial angiography & angioplasty, Coronary artery stenting, CT Coronary angiography, Peripheral angiogram & angioplasty (carotid, subclavian, lilac femoral, renal, etc.), and Temporary Pacemaker Implantation.

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Cath-Lab gmc 1

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 21,2020

Jan 21: Info Edge (India)'s shareholding in Zomato reduces to 22.71%; Uber receives 9.99% stake in Zomato.

Info Edge (India) announced that Zomato Media (Zomato) has signed a definitive agreement to acquire Uber's food delivery business in India (Uber) in an all-stock transaction, which gives Uber 9.99% ownership in Zomato.

Uber Eats in India will discontinue operations and direct restaurants, delivery partners, and users of the Uber Eats apps to the Zomato platform, effective 21 January 2020.

Upon closing of said acquisition, the company's shareholding in Zomato shall stand reduced to about 22. 71 % on fully converted & diluted basis.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 6,2020
Mangaluru, Apr 6: Agricultural produce vendors have decided to hold an indefinite strike from Monday here in city's Central Market.
 
This move comes in response to district administration’s order asking them to shift to the APMC yard at Baikampady and not heeding to their appeal to allow them to operate from the Market and other areas in the city.
 
The district administration has decided to shift the vendors in order to prevent crowding in the market and maintain social distancing norms.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 27,2020

Bengaluru, Mar 27: Oncologist Dr. Vishal Rao, HCG Hospital Bengaluru on Friday said that human body cells release interferon chemical to kill viruses but it cannot be released by cells in the case of COVID-19 cases, leading to weak immune system. However, a therapy of specific concoction could be useful in treating COVID-19 patients.

"We got hold of some preprint suggesting that interferon is effective in COVID19," said Rao.

Speaking to news agency, he continued saying "When we withdraw blood for regular check-ups, we get buffy coat which can be used to take out cells and form interferon. These two chemicals and some other cytokines, in a specific concoction, could be potentially very useful in treating COVID-19 patients."

Rao said that they have built a concoction of cytokines which can be injected to reactivate immune system in COVID-19 patients.

"We are in a very initial stage and hope to be ready with its first set by this weekend. We have applied to the governement for an expedited review. We have also presented this before the state government" said Rao.

"We have a team of infection specialist, ICU team and other...all of us have worked together to build something that we believe. We want to serve the society at this hour of need," he added.

Dr Rao clarified that this is not a vaccine and this particular interferon therapy does not help to prevent the infection of COVID-19. However, this is focused and targeted towards COVID-19 positive patients or those who have just incubated the virus.

"We believe that in early stages as well as the patients who have just incubated, this particular therapy of interferon gama and other concoction of cytokines could be an effective method. In the late stages we are looking at specific dosage of the cells which are our own body cells which can actually be affective and could also be of use for the ventilator patients," he added.

Meanwhile, Dr Gururaj, Immunologist and Scientist told ANI that they are trying to cover two aspects, one is the early stage patients where they are trying to improve their immune systems.

"As Dr Vishal said, we are trying to see whether we can use the cytokines from our own immune cells which is a natural process but it is hampered in infected patients," said Dr Gururaj.

"In the last phase we are using cells which are used from the bone marrow of the patient or donors. We can use those cells to reduce the inflation and so called cytokines release syndrome which is basically the inflammatory response of the body," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.